Skip to main content
Clinical Trials/NCT01461746
NCT01461746
Unknown
Phase 2

A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery

Asan Medical Center1 site in 1 country67 target enrollmentOctober 2011

Overview

Phase
Phase 2
Intervention
Docetaxel
Conditions
Endometrial Cancer
Sponsor
Asan Medical Center
Enrollment
67
Locations
1
Primary Endpoint
Progression-free survival
Last Updated
8 years ago

Overview

Brief Summary

Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin which is currently used in most cases. However, docetaxel plus cisplatin may cause less toxicity compared to paclitaxel plus carboplatin. Therefore, the investigators aimed to analyze the efficacy of docetaxel plus cisplatin regimen followed by radiation therapy after surgery in patients with high risk endometrial cancer.

Registry
clinicaltrials.gov
Start Date
October 2011
End Date
December 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joo-Hyun Nam

Professor

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • One of following high risk groups Stage III after staging operation Stage II (Type I hysterectomy + BSO + LND) Stage I + two of \[Grade III, LVSI+, Mm\>1/2\] Clear cell or serous carcinoma: stage IB-II
  • Age: 20-75
  • ECOG PS: 0-2
  • Adequate organ function BM: WBC ≥ 3,000/mm3, ANC≥1,500/mm3, Plt≥100X103/mm3, Hb≥10.0 g/dl Kidney: Creatinine \<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT\< 3×UNL, T- bil\<1.5 mg/ mm3
  • Informed Consent

Exclusion Criteria

  • Previous chemotherapy or pelvic RT
  • Hormone therapy within 4 weeks
  • Other malignant disease
  • Uncontrolled medical disease
  • Infection requiring antibiotics
  • Symptomatic CHF, RF, Angina, Arrhythmia, etc.
  • Neurosis or psychosis

Arms & Interventions

Chemotherpay and radiation therapy

Docetaxel plus cisplatin followed by radiation therapy

Intervention: Docetaxel

Chemotherpay and radiation therapy

Docetaxel plus cisplatin followed by radiation therapy

Intervention: Cisplatin

Chemotherpay and radiation therapy

Docetaxel plus cisplatin followed by radiation therapy

Intervention: Radiation therapy

Outcomes

Primary Outcomes

Progression-free survival

Time Frame: 2 years after completion of study treatment

Secondary Outcomes

  • Overall survival(2 years after completion of study treatment)
  • Quality of life(3 months after completion of study treatment)
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability(Before each chemotherapy, an expected average of 3 weeks)

Study Sites (1)

Loading locations...

Similar Trials